Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Fluorothiazinon, a small-molecular inhibitor of T3SS, suppresses salmonella oral infection in mice

The Journal of Antibiotics volume 74, pages 244–254 (2021)Cite this article

Subjects

Abstract

Therapeutic strategies that target bacterial virulence have received considerable attention. The type III secretion system (T3SS) is important for bacterial virulence and represents an attractive therapeutic target. Recently, we developed a new small-molecule inhibitor belonging to a class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones, Fluorothiazinon (FT—previously called CL-55). FT effectively suppressed T3SS of Chlamydia spp., Pseudomonas aeruginosa, and Salmonella without affecting bacterial growth in vitro. FT was previously characterized by low toxicity, stability, and therapeutic efficacy in animal models. Salmonella T3SS inhibition by FT was studied using in vitro assays for effector proteins detection and estimation of salmonella replication in peritoneal macrophages. The antibacterial effect of FT in vivo was investigated in murine models of salmonella chronic systemic and acute infection. Oral administration of the virulent strain of Salmonella enterica serovar Typhimurium to mice-induced chronic systemic infection with the pathogen persistence in different lymphoid organs such as spleens, Peyer’s plaques, and mesenteric lymph nodes. We found that FT suppressed orally induced salmonella infection both with therapeutic and prophylactic administration. Treatment by FT at a dose of 50 mg/kg for 4 days starting from day 7 post-infection (therapy) as well as for 4 days before infection (prevention) led to practically complete eradication of salmonella in mice. FT shows a strong potential for antibacterial therapy and could be used as a substance in the design of antibacterial drugs for pharmaceutical intervention including therapy of antibiotic-resistant infections.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Qianghua LV, et al. Inhibition of the type III secretion system by syringaldehyde protects mice from Salmonella enterica serovar Typhimurium. J Cell Mol Med. 2019;23:4679–88.

    Article  Google Scholar 

  2. Gal-Mor O. Persistent infection and long-term carriage of typhoidal and nontyphoidal Salmonellae. Clin Microbiol Rev. 2019;32:1–31.

    Google Scholar 

  3. Knodler LA. Salmonella enterica: living a double life in epithelial cells. Curr Opin Microbiol. 2015;23:23–31.

    Article  CAS  Google Scholar 

  4. WHO. Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics 2017. https://www.who.int/news-room/detail/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed.

  5. Czaplewski L, et al. Alternatives to antibiotics-a pipeline portfolio review. Lancet Infect Dis. 2016;16:239–51.

    Article  CAS  Google Scholar 

  6. Munguia J, Nizet V. Pharmacological targeting of the host-pathogen interaction: alternatives to classical antibiotics to combat drug-resistant superbugs. Trends Pharm Sci. 2017;38:473–88.

    Article  CAS  Google Scholar 

  7. Allen RC, Popat R, Diggle SP, Brown SP. Targeting virulence: can we make evolution-proof drugs? Nat Rev Microbiol. 2014;12:300–8.

    Article  CAS  Google Scholar 

  8. Theuretzbacher U, Piddock LJV. Non-traditional antibacterial therapeutic options and challenges. Cell Host Microbe. 2019;26:61–72.

    Article  CAS  Google Scholar 

  9. McShan AC, De, Guzman RN. The bacterial type III secretion system as a target for developing new antibiotics. Chem Biol Drug Des. 2015;85:30–42.

    Article  CAS  Google Scholar 

  10. Fasciano AC, Shaban L, Mecsas J. Promises and challenges of the type three secretion system injectisome as an antivirulence target. In: Sandkvist M, Cascales E, Christie PJ, editors. Protein Secretion in Bacteria. Chapter 21. Wiley Online Library: https://doi.org/10.1128/9781683670285. 2019; p. 261–276

  11. Charro N, Mota LJ. Approaches targeting the type III secretion system to treat or prevent bacterial infections. Expert Opin Drug Discov. 2015;10:373–87.

    Article  CAS  Google Scholar 

  12. Duncan MC, Linington RG, Auerbuch V. Chemical inhibitors of the type three secretion system: disarming bacterial pathogens. Antimicrob Agents Chemother. 2012;56:5433–41.

    Article  CAS  Google Scholar 

  13. Zhang Y, Liu Y, Wang T, Deng X, Chu X. Natural compound sanguinarine chloride targets the type III secretion system of Salmonella enterica Serovar Typhimurium. Biochem Biophys Rep. 2018;14:149–54.

    PubMed  PubMed Central  Google Scholar 

  14. Nesterenko LN, et al. A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones suppresses Salmonella infection in vivo. J Antibiot. 2016;69:422–7.

    Article  CAS  Google Scholar 

  15. Zigangirova NA, et al. A small-molecule compound belonging to a class of 2,4-disubstituted 1,3,4-thiadiazine-5-ones inhibits intracellular growth and persistence of Chlamydia trachomatis. J Med Microbiol. 2016;65:91–8.

    Article  CAS  Google Scholar 

  16. Koroleva EA, et al. Small molecule inhibitor of type three secretion suppresses acute and chronic Chlamydia trachomatis infection in a novel urogenital Chlamydia model. Biomed Res Int. 2015;2015:484853.

    Article  Google Scholar 

  17. Zigangirova NA, et al. Development of Chlamydial type III secretion system inhibitors for suppression of acute and chronic forms of Chlamydial infection. Acta Nat. 2012;4:87–97.

    Article  CAS  Google Scholar 

  18. Sheremet AB, et al. Small molecule inhibitor of type three secretion system belonging to a class 2,4-disubstituted-4h-[1,3,4]-thiadiazine-5-ones improves survival and decreases bacterial loads in an airway Pseudomonas aeruginosa infection in mice. Biomed Res Int. 2018;2018:5810767.

    Article  Google Scholar 

  19. Negrea A, et al. Salicylidene acylhydrazides that affect type III protein secretion in Salmonella enterica serovar Typhimurium. Antimicrob Agents Chemother. 2007;51:2867–76.

    Article  CAS  Google Scholar 

  20. Nesterenko LN, et al. Mycobacterium tuberculosis-susceptible I/St mice develop severe disease following infection with taxonomically distant bacteria, Salmonella enterica and Chlamydia pneumoniae. Clin Exp Immunol. 2006;146:93–100.

    Article  CAS  Google Scholar 

  21. Figueira R, Watson KG, Holden DW, Helaine S. Identification of salmonella pathogenicity island-2 type III secretion system effectors involved in intramacrophage replication of S. enterica serovar Typhimurium: implications for rational vaccine design. mBio. 2013;4:e00065.

    Article  Google Scholar 

  22. Kobets NV, Nesterenko LN, Balunets DV. Local and systemic immune responses to Salmonella in genetically susceptible I/St mice after mucosal challenge. ISRN Immunol. 2013;2013:7.

    Article  Google Scholar 

  23. Zha L, Garrett S, Sun J. Salmonella infection in chronic inflammation and gastrointestinal cancer. Diseases. 2019;7:1–14.

    Article  Google Scholar 

  24. Palmer AD, Slauch JM. Mechanisms of Salmonella pathogenesis in animal models. Hum Ecol Risk Assess. 2017;23:1877–92.

    Article  CAS  Google Scholar 

  25. Monack DM, Bouley DM, Falkow S. Salmonella typhimurium persists within macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ mice and can be reactivated by IFNgamma neutralization. J Exp Med. 2004;199:231–41.

    Article  CAS  Google Scholar 

  26. Gunn JS, et al. Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence. Trends Microbiol. 2014;22:648–55.

    Article  CAS  Google Scholar 

  27. Karatzas KA, et al. Phenotypic and proteomic characterization of multiply antibiotic-resistant variants of Salmonella enterica serovar Typhimurium selected following exposure to disinfectants. Appl Environ Microbiol. 2008;74:1508–16.

    Article  CAS  Google Scholar 

  28. Wang M, Qazi IH, Wang L, Zhou G, Han H. Salmonella virulence and immune escape. Microorganisms. 2020;8:1–25.

    Google Scholar 

  29. Buckner MM, Croxen MA, Arena ET, Finlay BB. A comprehensive study of the contribution of Salmonella enterica serovar Typhimurium SPI2 effectors to bacterial colonization, survival, and replication in typhoid fever, macrophage, and epithelial cell infection models. Virulence 2011;2:208–16.

    Article  Google Scholar 

  30. Jennings E, Thurston TLM, Holden DW. Salmonella SPI-2 type iii secretion system effectors: molecular mechanisms and physiological consequences. Cell Host Microbe. 2017;22:217–31.

    Article  CAS  Google Scholar 

  31. Figueira R, Holden DW. Functions of the Salmonella pathogenicity island 2 (SPI-2) type III secretion system effectors. Microbiology. 2012;158(Pt 5):1147–61.

    Article  CAS  Google Scholar 

  32. Mastroeni P, Grant AJ. Spread of Salmonella enterica in the body during systemic infection: unravelling host and pathogen determinants. Expert Rev Mol Med. 2011;13:e12.

    Article  Google Scholar 

  33. Anantharajah A, Mingeot-Leclercq MP, Van Bambeke F. Targeting the type three secretion system in Pseudomonas aeruginosa. Trends Pharm Sci. 2016;37:734–49.

    Article  CAS  Google Scholar 

  34. Anantharajah A, et al. Salicylidene acylhydrazides and hydroxyquinolines act as inhibitors of type three secretion systems in Pseudomonas aeruginosa by distinct mechanisms. Antimicrob Agents Chemother. 2017;61:1–17.

    Article  Google Scholar 

  35. De Tavernier E, et al. High throughput combinatorial formatting of PcrV nanobodies for efficient potency improvement. J Biol Chem. 2016;291:15243–55.

    Article  Google Scholar 

  36. Thanabalasuriar A, et al. Bispecific antibody targets multiple Pseudomonas aeruginosa evasion mechanisms in the lung vasculature. J Clin Investig. 2017;127:2249–61.

    Article  Google Scholar 

  37. Le HN, et al. Treatment efficacy of MEDI3902 in Pseudomonas aeruginosa bloodstream infection and acute pneumonia rabbit models. Antimicrob Agents Chemother. 2019;63:5.

    Article  Google Scholar 

  38. Anantharajah A, et al. Inhibition of the injectisome and flagellar type iii secretion systems by INP1855 impairs Pseudomonas aeruginosa pathogenicity and inflammasome activation. J Infect Dis. 2016;214:1105–16.

    Article  CAS  Google Scholar 

  39. McHugh RE, O’Boyle N, Connolly JPR, Hoskisson PA, Roe AJ. Characterization of the mode of action of aurodox, a type iii secretion system inhibitor from Streptomyces goldiniensis. Infect Immun. 2019;87:12.

    Article  Google Scholar 

  40. Kimura K, et al. A small-molecule inhibitor of the bacterial type III secretion system protects against in vivo infection with Citrobacter rodentium. J Antibiot. 2011;64:197–203.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from the Russian Ministry of Science and Education and the Russian Ministry of Industry.

Author information

Authors and Affiliations

  1. Gamaleya National Research Center of Epidemiology and Microbiology, Ministry of Health Russian Federation, Gamaleya str.18, Moscow, 123098, Russia

    Nailya A. Zigangirova, Ludmila N. Nesterenko, Anna B. Sheremet, Anna V. Soloveva, Sergey I. Luyksaar, Egor S. Zayakin, Denis V. Balunets & Alexandr L. Gintsburg

Authors
  1. Nailya A. Zigangirova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ludmila N. Nesterenko
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Anna B. Sheremet
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anna V. Soloveva
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Sergey I. Luyksaar
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Egor S. Zayakin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Denis V. Balunets
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alexandr L. Gintsburg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nailya A. Zigangirova.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zigangirova, N.A., Nesterenko, L.N., Sheremet, A.B. et al. Fluorothiazinon, a small-molecular inhibitor of T3SS, suppresses salmonella oral infection in mice. J Antibiot 74, 244–254 (2021). https://doi.org/10.1038/s41429-020-00396-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41429-020-00396-w

This article is cited by

Search

Advanced search

Quick links